Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

[1]  Studies , 1926 .

[2]  W. Kalow,et al.  The relation between dose of succinylcholine and duration of apnea in man. , 1957, The Journal of pharmacology and experimental therapeutics.

[3]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[4]  E. Vesell,et al.  Genetic Control of Drug Levels in Man: Phenylbutazone , 1968, Science.

[5]  E. Vesell,et al.  Genetic control of dicumarol levels in man. , 1968, The Journal of clinical investigation.

[6]  E. Vesell,et al.  Genetic Control of Drug Levels in Man: Antipyrine , 1968, Science.

[7]  B. Alexanderson,et al.  Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy , 1969, British medical journal.

[8]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[9]  C. Dollery,et al.  HYDRALAZINE-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS: INFLUENCE OF HLA-DR AND SEX ON SUSCEPTIBILITY , 1980, The Lancet.

[10]  B. Dvorchik,et al.  Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Bonow,et al.  A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. , 1983 .

[12]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[13]  E. Vesell,et al.  Polymorphism of theophylline metabolism in man. , 1985, The Journal of clinical investigation.

[14]  R. Olson,et al.  The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. , 1987, The Journal of biological chemistry.

[15]  R. Olson,et al.  Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Roujeau,et al.  Toxic epidermal necrolysis (Lyell syndrome). , 1990, Journal of the American Academy of Dermatology.

[17]  B. Rzany,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. , 1991, Archives of dermatology.

[18]  G. M. Wilson,et al.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.

[19]  D. Iarussi,et al.  Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. , 1994, Molecular aspects of medicine.

[20]  J. Cheverud,et al.  Epistasis and its contribution to genetic variance components. , 1995, Genetics.

[21]  J. Lieberman,et al.  HLA associations in clozapine-induced agranulocytosis , 1995 .

[22]  J. Haines,et al.  A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.

[23]  M. Mockenhaupt,et al.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. , 1996, Journal of clinical epidemiology.

[24]  K. Pile,et al.  Aspirin‐induced asthma and HLA‐DRB1 and HLA‐DPB1 genotypes , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  P. Gasparini,et al.  Fixed drug eruptions with feprazone are linked to HLA-B22. , 1997, Journal of the American Academy of Dermatology.

[26]  L. A. Sawyer,et al.  Natural variation in a Drosophila clock gene and temperature compensation. , 1997, Science.

[27]  T. Carrillo,et al.  Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs. , 1999, The Journal of allergy and clinical immunology.

[28]  C. Sempoux,et al.  HLA association of amoxicillin-clavulanate--induced hepatitis. , 1999, Gastroenterology.

[29]  J. Gulcher,et al.  An Icelandic saga on a centralized healthcare database and democratic decision making , 1999, Nature Biotechnology.

[30]  R. N. Macsween,et al.  Co-amoxiclav jaundice: clinical and histological features and HLA class II association , 2000, Gut.

[31]  H. Sather,et al.  Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[33]  U. Akar,et al.  Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. , 2001, Journal of the American Academy of Dermatology.

[34]  V. Pirrotta,et al.  Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites , 2002, Cell.

[35]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[36]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[37]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[38]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[39]  G. Francis,et al.  Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon-β-1a , 2003 .

[40]  H. Chng,et al.  Drug allergy in a general hospital: Results of a novel prospective inpatient reporting system. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[41]  M. Romeih,et al.  Function of RARγ and RARα2 at the initiation of retinoid signaling is essential for avian embryo survival and for distinct events in cardiac morphogenesis , 2003 .

[42]  G. Francis,et al.  Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. , 2003, Drug safety.

[43]  R. Farinotti,et al.  A 6‐month prospective survey of cutaneous drug reactions in a hospital setting , 2003, The British journal of dermatology.

[44]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[45]  T. Rebbeck,et al.  CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia , 2003, British journal of haematology.

[46]  Peter A. Jones,et al.  Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[48]  E. Cook,et al.  Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  I. James,et al.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Yi Huang,et al.  Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells. , 2004, Molecular cancer therapeutics.

[51]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[52]  W. Kamps,et al.  Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic Leukemia , 2003, Clinical pharmacology and therapeutics.

[53]  Choon-Sik Park,et al.  HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. , 2004, The Journal of allergy and clinical immunology.

[54]  R. Shanks,et al.  Can severe vincristine neurotoxicity be prevented? , 2004, Cancer Chemotherapy and Pharmacology.

[55]  H. Sather,et al.  Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961 , 2004, Journal of pediatric hematology/oncology.

[56]  M. Eichelbaum,et al.  Influence of the defective metabolism of sparteine on its pharmacokinetics , 1979, European Journal of Clinical Pharmacology.

[57]  G. Salles,et al.  Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  M. Pirmohamed,et al.  Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. , 2004, Pharmacogenetics.

[59]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[60]  H. Tremlett,et al.  Liver injury associated with the β-interferons for MS , 2004, Neurology.

[61]  Choon-Sik Park,et al.  Leukotriene-related Gene Polymorphisms in Patients with Aspirin-intolerant Urticaria and Aspirin-intolerant Asthma: Differing Contributions of ALOX5 Polymorphism in Korean Population , 2005, Journal of Korean medical science.

[62]  J. Heimans,et al.  Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening , 2005, Neurology.

[63]  C. Suh,et al.  The human leucocyte antigen‐DRB1*1302‐DQB1*0609‐DPB1*0201 haplotype may be a strong genetic marker for aspirin‐induced urticaria , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[64]  Á. Raya,et al.  Epicardial retinoid X receptor is required for myocardial growth and coronary artery formation , 2005 .

[65]  Yuan-Tsong Chen,et al.  HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Moore,et al.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.

[67]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[68]  Amparo Hernández-Salazar,et al.  Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. , 2006, Archives of medical research.

[69]  C. Guillemette,et al.  Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer , 2006, Clinical Cancer Research.

[70]  S. Mallal,et al.  Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  C. Allis,et al.  Mouse Polycomb Proteins Bind Differentially to Methylated Histone H3 and RNA and Are Enriched in Facultative Heterochromatin , 2006, Molecular and Cellular Biology.

[72]  C. Carcassi,et al.  HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients , 2006, AIDS.

[73]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[74]  M. McElrath,et al.  Abacavir hypersensitivity reaction in primary HIV infection , 2006, AIDS.

[75]  David M. Reif,et al.  Novel methods for detecting epistasis in pharmacogenomics studies. , 2007, Pharmacogenomics.

[76]  H. Yazaki,et al.  HLA-Cw8 primarily associated with hypersensitivity to nevirapine. , 2007, AIDS.

[77]  Z. Ikezawa,et al.  Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan , 2007 .

[78]  Z. Ikezawa,et al.  Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. , 2007, Allergology international : official journal of the Japanese Society of Allergology.

[79]  A. Mortazavi,et al.  Genome-Wide Mapping of in Vivo Protein-DNA Interactions , 2007, Science.

[80]  V. Soriano,et al.  Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. , 2007, AIDS research and human retroviruses.

[81]  H. Blum,et al.  Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs , 2007, Cancer Gene Therapy.

[82]  Jennifer B Dennison,et al.  Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes , 2007, Journal of Pharmacology and Experimental Therapeutics.

[83]  C. Allis,et al.  DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA , 2007, Nature.

[84]  K. Suphapeetiporn,et al.  Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population , 2008, Epilepsia.

[85]  Chan Sun Park,et al.  The use of an electronic medical record system for mandatory reporting of drug hypersensitivity reactions has been shown to improve the management of patients in the university hospital in Korea , 2008, Pharmacoepidemiology and drug safety.

[86]  S. Bates,et al.  Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells , 2008, Molecular Cancer Research.

[87]  Michael Q. Zhang,et al.  Genome-wide mapping and analysis of active promoters in mouse embryonic stem cells and adult organs. , 2007, Genome research.

[88]  M. Peppelenbosch,et al.  Modulation of Src Activity by Low Molecular Weight Protein Tyrosine Phosphatase During Osteoblast Differentiation , 2008, Cellular Physiology and Biochemistry.

[89]  M. Neurath,et al.  The transcription factor NFATc2 controls IL-6–dependent T cell activation in experimental colitis , 2008, The Journal of experimental medicine.

[90]  S. Mallal,et al.  HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.

[91]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[92]  H. Takagi,et al.  Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study , 2008, The Pharmacogenomics Journal.

[93]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[94]  T. Taniguchi,et al.  The IRF family transcription factors in immunity and oncogenesis. , 2008, Annual review of immunology.

[95]  S. Mallal,et al.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  Z. Weng,et al.  High-Resolution Mapping and Characterization of Open Chromatin across the Genome , 2008, Cell.

[97]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[98]  A. Hovnanian,et al.  HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz , 2008, AIDS.

[99]  M. Relling,et al.  A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[100]  B. Gazzard.  British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.

[101]  Seon-Yong Jeong,et al.  Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3β , 2009, Journal of Bone and Mineral Metabolism.

[102]  M. Relling,et al.  Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer , 2008, Cancer.

[103]  Judy H. Cho,et al.  Finding the missing heritability of complex diseases , 2009, Nature.

[104]  O. Poch,et al.  Cell-Specific Interaction of Retinoic Acid Receptors with Target Genes in Mouse Embryonic Fibroblasts and Embryonic Stem Cells , 2009, Molecular and Cellular Biology.

[105]  Yusuke Nakamura,et al.  HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients , 2009, Pharmacogenetics and genomics.

[106]  Jim Vaught,et al.  A review of international biobanks and networks: success factors and key benchmarks. , 2009, Biopreservation and biobanking.

[107]  J. Mullikin,et al.  Genomic features defining exonic variants that modulate splicing , 2010, Genome Biology.

[108]  C. Joshi,et al.  Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. , 2009, Indian journal of dermatology, venereology and leprology.

[109]  V. Stone,et al.  Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[110]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[111]  M. Daly,et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin , 2009, Nature Genetics.

[112]  B. Giardina,et al.  New developments in anthracycline-induced cardiotoxicity. , 2009, Current medicinal chemistry.

[113]  M. Shirakawa,et al.  Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX–DNMT3–DNMT3L domain , 2009, EMBO reports.

[114]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[115]  W. Prasithsirikul,et al.  HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients , 2009, AIDS research and therapy.

[116]  E. R. Sutherland,et al.  Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial , 2009, The Lancet.

[117]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[118]  S. Purcell,et al.  A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. , 2009, The American journal of psychiatry.

[119]  S. Turner,et al.  Real-Time DNA Sequencing from Single Polymerase Molecules , 2009, Science.

[120]  S. Hart,et al.  Dynamic Patterns of Histone Methylation Are Associated with Ontogenic Expression of the Cyp3a Genes during Mouse Liver Maturation , 2009, Molecular Pharmacology.

[121]  Howard Y. Chang,et al.  ING4 mediates crosstalk between histone H3 K4 trimethylation and H3 acetylation to attenuate cellular transformation. , 2009, Molecular cell.

[122]  A. Miyajima,et al.  Functional analysis of GC Box and its CpG methylation in the regulation of CYP1A2 gene expression. , 2009, Drug metabolism and pharmacokinetics.

[123]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[124]  I. Mlinarič-Raščan,et al.  Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood , 2009, Leukemia & lymphoma.

[125]  M. Bedford,et al.  Epigenetic Regulation of Transcriptional Activity of Pregnane X Receptor by Protein Arginine Methyltransferase 1* , 2009, Journal of Biological Chemistry.

[126]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[127]  M. Biel,et al.  Tissue Distribution of 5-Hydroxymethylcytosine and Search for Active Demethylation Intermediates , 2010, PloS one.

[128]  P. Kwan,et al.  Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China , 2010, Epilepsy & Behavior.

[129]  C. Dumontet,et al.  Microtubule-binding agents: a dynamic field of cancer therapeutics , 2010, Nature Reviews Drug Discovery.

[130]  Jie Lv,et al.  HHMD: the human histone modification database , 2009, Nucleic Acids Res..

[131]  S. Lewitzky,et al.  OC-035 Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis , 2010, Gut.

[132]  S. Mallal,et al.  Pharmacogenetics of drug hypersensitivity. , 2010, Pharmacogenomics.

[133]  E. Wolf,et al.  Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany , 2010, European journal of medical research.

[134]  L. French,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome , 2010, Orphanet journal of rare diseases.

[135]  M. Pirmohamed,et al.  Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. , 2010, Journal of hepatology.

[136]  Gaurav Sharma,et al.  TurboFold: Iterative probabilistic estimation of secondary structures for multiple RNA sequences , 2011, BMC Bioinformatics.

[137]  M. Relling,et al.  Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity , 2010, Clinical pharmacology and therapeutics.

[138]  C. Pui,et al.  Glucocorticoid use in acute lymphoblastic leukaemia. , 2010, The Lancet. Oncology.

[139]  Tyson A. Clark,et al.  Direct detection of DNA methylation during single-molecule, real-time sequencing , 2010, Nature Methods.

[140]  Robert B. Hartlage,et al.  This PDF file includes: Materials and Methods , 2009 .

[141]  Hye‐Ryun Kang,et al.  HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2010, Pharmacogenomics.

[142]  C. E. Pearson,et al.  Table S2: Trans-factors and trinucleotide repeat instability Trans-factor , 2010 .

[143]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[144]  D. Weinberger,et al.  MicroSNiPer: a web tool for prediction of SNP effects on putative microRNA targets , 2010, Human mutation.

[145]  S. Tiamkao,et al.  Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai population , 2010, Epilepsia.

[146]  C. Sotozono,et al.  HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients , 2010, Epilepsia.

[147]  M. D. Den Boer,et al.  Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. , 2010, Leukemia research.

[148]  InSook Cho,et al.  Design and implementation of a standards-based interoperable clinical decision support architecture in the context of the Korean EHR , 2010, Int. J. Medical Informatics.

[149]  J. Jung,et al.  Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans , 2011, Pharmacogenetics and genomics.

[150]  Yusuke Nakamura,et al.  Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .

[151]  M. Relling,et al.  Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. , 2010, Blood.

[152]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[153]  P. Thibault,et al.  H3 Lysine 4 Is Acetylated at Active Gene Promoters and Is Regulated by H3 Lysine 4 Methylation , 2011, PLoS genetics.

[154]  M. Daly,et al.  Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. , 2011, Gastroenterology.

[155]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[156]  Chuan He,et al.  Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine , 2011, Science.

[157]  J. Holdway,et al.  Retinoic acid production by endocardium and epicardium is an injury response essential for zebrafish heart regeneration. , 2011, Developmental cell.

[158]  K. Zhao,et al.  ChIP-Seq: technical considerations for obtaining high-quality data , 2011, Nature Immunology.

[159]  N. André,et al.  Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity , 2011, Cancer Chemotherapy and Pharmacology.

[160]  Dong Zhou,et al.  Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population , 2011, Seizure.

[161]  J. Jung,et al.  HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[162]  Limei Zhao,et al.  Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients , 2011, European Journal of Clinical Pharmacology.

[163]  A. Romano,et al.  Diagnosis and management of drug hypersensitivity reactions. , 2011, The Journal of allergy and clinical immunology.

[164]  P. Grant,et al.  Sgf29 binds histone H3K4me2/3 and is required for SAGA complex recruitment and histone H3 acetylation , 2011, The EMBO journal.

[165]  S. Hall,et al.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.

[166]  V. Haufroid,et al.  Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition , 2011, Pharmacogenetics and genomics.

[167]  P. Visscher,et al.  Estimating missing heritability for disease from genome-wide association studies. , 2011, American journal of human genetics.

[168]  Leah B. Honor,et al.  Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. , 2011, The Journal of clinical investigation.

[169]  C. Pui,et al.  L‐asparaginase treatment in acute lymphoblastic leukemia , 2011, Cancer.

[170]  S. Murad,et al.  Association of HLA‐B*1502 allele with carbamazepine‐induced toxic epidermal necrolysis and Stevens–Johnson syndrome in the multi‐ethnic Malaysian population , 2011, International journal of dermatology.

[171]  Yi-wu Shi,et al.  Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. , 2011, Basic & clinical pharmacology & toxicology.

[172]  R. Jamal,et al.  Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. , 2011, Asian Pacific journal of allergy and immunology.

[173]  Sang-Heon Cho,et al.  Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans , 2011, Epilepsy Research.

[174]  H. Goldschmidt,et al.  Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  J. Duley,et al.  Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited‐sampling, population modelling approach , 2011, Journal of paediatrics and child health.

[176]  K. King,et al.  HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  Q. Wang,et al.  Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland , 2011, Seizure.

[178]  W. Hop,et al.  Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  G. Crawford,et al.  H3K4me3 inversely correlates with DNA methylation at a large class of non-CpG-island-containing start sites , 2012, Genome Medicine.

[180]  D. Podzamczer,et al.  Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent , 2011, AIDS.

[181]  L. Milani,et al.  DNA methylation dynamics in the hepatic CYP3A4 gene promoter. , 2012, Biochimie.

[182]  G. Rosner,et al.  Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. , 2012, Genome research.

[183]  S. Mallal,et al.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire , 2012, Proceedings of the National Academy of Sciences.

[184]  M. Relling,et al.  Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia , 2011, Leukemia.

[185]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[186]  D. Margulies,et al.  Abacavir induces loading of novel self-peptides into HLA-B*57: 01 an autoimmune model for HLA-associated drug hypersensitivity , 2012, AIDS.

[187]  S. Tiamkao,et al.  HLA‐B*1502 Strongly Predicts Carbamazepine‐Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients with Neuropathic Pain , 2012, Pain practice : the official journal of World Institute of Pain.

[188]  G. Hon,et al.  Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome , 2012, Cell.

[189]  C. Flores,et al.  Genetic variants of the arachidonic acid pathway in non‐steroidal anti‐inflammatory drug‐induced acute urticaria , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[190]  J. Miller,et al.  Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.

[191]  T. Kakamu,et al.  HLA‐A31 strongly associates with carbamazepine‐induced adverse drug reactions but not with carbamazepine‐induced lymphocyte proliferation in a Japanese population , 2012, The Journal of dermatology.

[192]  Yuan-Tsong Chen,et al.  Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. , 2012, The Journal of allergy and clinical immunology.

[193]  E. Finkelstein,et al.  Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore , 2012, Neurology.

[194]  J. McCluskey,et al.  Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. , 2012, Annual review of pharmacology and toxicology.

[195]  J. Graham,et al.  Single-Nucleotide Polymorphisms in Aldo-Keto and Carbonyl Reductase Genes Are Not Associated with Acute Cardiotoxicity after Daunorubicin Chemotherapy , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[196]  L. Lesko,et al.  Individualization of Drug Therapy: History, Present State, and Opportunities for the Future , 2012, Clinical pharmacology and therapeutics.

[197]  Claudio J. Verzilli,et al.  An Abundance of Rare Functional Variants in 202 Drug Target Genes Sequenced in 14,002 People , 2012, Science.

[198]  L. Tokgözoğlu,et al.  The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms , 2012, Journal of chemotherapy.

[199]  M. Relling,et al.  Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  S. Strauss,et al.  Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma , 2012, Cancer.

[201]  A. Falus,et al.  ABCC1 polymorphisms in anthracycline‐induced cardiotoxicity in childhood acute lymphoblastic leukaemia , 2012, Cell biology international.

[202]  William Stafford Noble,et al.  Unsupervised pattern discovery in human chromatin structure through genomic segmentation , 2012, Nature Methods.

[203]  S. Balasubramanian,et al.  Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution , 2012, Science.

[204]  Y. Ye,et al.  Genetic variability of prostaglandin E2 receptor subtype EP4 gene in aspirin-intolerant chronic urticaria , 2012, Journal of Human Genetics.

[205]  J. McCluskey,et al.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.

[206]  M. Pirmohamed,et al.  HLA Genotype and Carbamazepine‐Induced Cutaneous Adverse Drug Reactions: A Systematic Review , 2012, Clinical pharmacology and therapeutics.

[207]  M. Hayden,et al.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[209]  F. Levy,et al.  Retinoic Acid Signalling Is Activated in the Postischemic Heart and May Influence Remodelling , 2012, PloS one.

[210]  K. Verstrepen,et al.  Background-dependent effects of polyglutamine variation in the Arabidopsis thaliana gene ELF3 , 2012, Proceedings of the National Academy of Sciences.

[211]  B. Horne,et al.  A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) , 2012, Circulation.

[212]  B. Bernstein,et al.  Histone H2A Mono-Ubiquitination Is a Crucial Step to Mediate PRC1-Dependent Repression of Developmental Genes to Maintain ES Cell Identity , 2012, PLoS genetics.

[213]  S. Mallal,et al.  HLA-B*5701 and flucloxacillin associated drug-induced liver disease. , 2013, AIDS.

[214]  N. Eriksson,et al.  A randomized trial of genotype-guided dosing of warfarin. , 2013, The New England journal of medicine.

[215]  M. Pan,et al.  NFAT gene family in inflammation and cancer. , 2013, Current molecular medicine.

[216]  M. Pirmohamed,et al.  Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[217]  M. Lederman,et al.  Associations Between HLA-DRB1*0102, HLA-B*5801, and Hepatotoxicity During Initiation of Nevirapine-Containing Regimens in South Africa , 2013, Journal of acquired immune deficiency syndromes.

[218]  M. Hayden,et al.  Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children , 2013, Pediatric blood & cancer.

[219]  O. Garrone,et al.  Role of the Renin-Angiotensin-Aldosterone System and the Glutathione S-Transferase Mu, Pi and Theta Gene Polymorphisms in Cardiotoxicity after Anthracycline Chemotherapy for Breast Carcinoma , 2013, The International journal of biological markers.

[220]  D. An,et al.  Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese , 2013, Epilepsy Research.

[221]  M. Gonçalo,et al.  HLA‐B*58:01 is a risk factor for allopurinol‐induced DRESS and Stevens–Johnson syndrome/toxic epidermal necrolysis in a Portuguese population , 2013, The British journal of dermatology.

[222]  Yi-wu Shi,et al.  The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a Northern Han Chinese population , 2013, BMC Neurology.

[223]  A. H. Smits,et al.  Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives , 2013, Cell.

[224]  M. Kilberg,et al.  Asparagine synthetase: regulation by cell stress and involvement in tumor biology. , 2013, American journal of physiology. Endocrinology and metabolism.

[225]  T. Marwick,et al.  Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. , 2013, Journal of the American College of Cardiology.

[226]  Jorge Oliveira,et al.  Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer , 2013, BMC Genomics.

[227]  Xiangsheng Chen,et al.  Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. , 2013, The Journal of investigative dermatology.

[228]  Takashi Sugamori,et al.  HLA-B*58:01 strongly associates with allopurinol-induced adverse drug reactions in a Japanese sample population. , 2013, Journal of dermatological science.

[229]  Á. Carracedo,et al.  Association of thromboxane A1 synthase (TBXAS1) gene polymorphism with acute urticaria induced by nonsteroidal anti-inflammatory drugs. , 2013, The Journal of allergy and clinical immunology.

[230]  S. Balasubramanian,et al.  A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation , 2013, Genome Biology.

[231]  Mehmet Deveci,et al.  mrSNP: Software to detect SNP effects on microRNA binding , 2014, BMC Bioinformatics.

[232]  W. Pichler,et al.  Sulfamethoxazole Induces a Switch Mechanism in T Cell Receptors Containing TCRVβ20-1, Altering pHLA Recognition , 2013, PloS one.

[233]  P. Radivojac,et al.  MutPred Splice: machine learning-based prediction of exonic variants that disrupt splicing , 2014, Genome Biology.

[234]  P. D. de Bakker,et al.  HLA-B*13:01 and the dapsone hypersensitivity syndrome. , 2013, The New England journal of medicine.

[235]  M. Ingelman-Sundberg,et al.  Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins , 2013, Clinical Cancer Research.

[236]  P. Kwan,et al.  HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese , 2013, Epilepsia.

[237]  I. Derrington,et al.  Detection and mapping of 5-methylcytosine and 5-hydroxymethylcytosine with nanopore MspA , 2013, Proceedings of the National Academy of Sciences.

[238]  S. Lipsitz,et al.  Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia , 2013, Cancer.

[239]  M. Ingelman-Sundberg,et al.  Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects , 2012, The Pharmacogenomics Journal.

[240]  W. Chung,et al.  Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore , 2013, Neurology.

[241]  M. Pirmohamed,et al.  Human leukocyte antigen (HLA)‐B*57:01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury , 2013, Hepatology.

[242]  J. Graham,et al.  A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor , 2013, Front. Genet..

[243]  M. Kals,et al.  Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function , 2013, Genome Biology.

[244]  T. Marwick,et al.  Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. , 2013, European journal of cancer.

[245]  S. Neuhausen,et al.  Genetic susceptibility to anthracycline‐related congestive heart failure in survivors of haematopoietic cell transplantation , 2013, British journal of haematology.

[246]  R. Califf,et al.  A pharmacogenetic versus a clinical algorithm for warfarin dosing. , 2013, The New England journal of medicine.

[247]  M. Ingelman-Sundberg,et al.  Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy , 2014, Clinical Cancer Research.

[248]  M. Akeson,et al.  Nanopores Discriminate among Five C5-Cytosine Variants in DNA , 2014, Journal of the American Chemical Society.

[249]  C. Queitsch,et al.  The overdue promise of short tandem repeat variation for heritability , 2014, bioRxiv.

[250]  E. Zeggini,et al.  Functional annotation of non-coding sequence variants , 2014, Nature Methods.

[251]  H. Hakonarson,et al.  Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[252]  T. Su,et al.  Variant GADL1 and response to lithium therapy in bipolar I disorder. , 2014, The New England journal of medicine.

[253]  W. Pichler,et al.  Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01 , 2014, The Journal of Immunology.

[254]  P. Kwan,et al.  Association between HLA-B*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study. , 2014, Hong Kong medical journal = Xianggang yi xue za zhi.

[255]  D. Neuberg,et al.  Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. , 2014, Pharmacogenomics.

[256]  T. Bonaldi,et al.  Biochemical systems approaches for the analysis of histone modification readout. , 2014, Biochimica et biophysica acta.

[257]  D. Neuberg,et al.  Polymorphisms of Asparaginase Pathway and Asparaginase-Related Complications in Children with Acute Lymphoblastic Leukemia , 2014, Clinical Cancer Research.

[258]  L. Lennard.  Implementation of TPMT testing. , 2014, British journal of clinical pharmacology.

[259]  M. Bonder,et al.  Genetic and epigenetic regulation of gene expression in fetal and adult human livers , 2014, BMC Genomics.

[260]  Yaoqi Zhou,et al.  Impact of human pathogenic micro-insertions and micro-deletions on post-transcriptional regulation. , 2014, Human molecular genetics.

[261]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[262]  Jennifer G. Robinson,et al.  Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. , 2014, Human molecular genetics.

[263]  S. Tsai,et al.  Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. , 2014, JAMA.

[264]  B. Peters,et al.  Personalized pharmacogenomics profiling using whole-genome sequencing. , 2014, Pharmacogenomics.

[265]  M. Loh,et al.  HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. , 2014, Blood.

[266]  R. Hui,et al.  Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. , 2014, Journal of dermatological science.

[267]  B. Drögemöller,et al.  Considerations for rare variants in drug metabolism genes and the clinical implications , 2014, Expert opinion on drug metabolism & toxicology.

[268]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[269]  D. Meyers,et al.  Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. , 2014, The Journal of allergy and clinical immunology.

[270]  M. Vermeulen,et al.  Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. , 2014, Nature chemical biology.

[271]  M. Ingelman-Sundberg,et al.  High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme , 2014, The Pharmacogenomics Journal.

[272]  E. Génin,et al.  HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis , 2013, The Pharmacogenomics Journal.

[273]  M. Daly,et al.  Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles , 2014, Nature Communications.

[274]  Elizabeth M. Wells,et al.  Patterns and severity of vincristine‐induced peripheral neuropathy in children with acute lymphoblastic leukemia , 2015, Journal of the peripheral nervous system : JPNS.

[275]  M. Loh,et al.  Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. , 2015, Blood.

[276]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[277]  R. Aaron,et al.  Pathophysiology and risk factors for osteonecrosis , 2015, Current Reviews in Musculoskeletal Medicine.

[278]  S. Balasubramanian,et al.  5-Formylcytosine can be a stable DNA modification in mammals. , 2015, Nature chemical biology.

[279]  M. Pirmohamed,et al.  Cost‐effectiveness of screening for HLA‐A*31:01 prior to initiation of carbamazepine in epilepsy , 2015, Epilepsia.

[280]  Imir G. Metushi,et al.  T cell-mediated hypersensitivity reactions to drugs. , 2015, Annual review of medicine.

[281]  M. Lee,et al.  Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015, BMJ : British Medical Journal.

[282]  Xiaojing Tang,et al.  Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication. , 2015, Current drug metabolism.

[283]  Melissa A. Basford,et al.  Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. , 2015, Blood.

[284]  Smita H. Karande,et al.  A Coding Variant in RARG Confers Susceptibility to Anthracycline-Induced Cardiotoxicity in Childhood Cancer , 2015, Nature Genetics.

[285]  B. Garcia,et al.  Quantitative proteomic analysis of histone modifications. , 2015, Chemical reviews.

[286]  P. Elliott,et al.  The Qatar Biobank: background and methods , 2015, BMC Public Health.

[287]  N. Goldman,et al.  The human blood DNA methylome displays a highly distinctive profile compared with other somatic tissues , 2015, Epigenetics.

[288]  M. Battaglini,et al.  Prognostic biomarkers of IFNb therapy in multiple sclerosis patients , 2015, Multiple sclerosis.

[289]  Julie A. Johnson,et al.  Warfarin pharmacogenetics. , 2015, Trends in cardiovascular medicine.

[290]  Shyang-Rong Shih,et al.  Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study , 2015, Nature Communications.

[291]  A. Romano,et al.  HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping. , 2015, The Journal of allergy and clinical immunology.

[292]  S. Balasubramanian,et al.  5-Formylcytosine alters the structure of the DNA double helix , 2014, Nature Structural &Molecular Biology.

[293]  N. Brockdorff,et al.  The interplay of histone modifications – writers that read , 2015, EMBO reports.

[294]  K. Chu,et al.  The HLA‐A*2402/Cw*0102 haplotype is associated with lamotrigine‐induced maculopapular eruption in the Korean population , 2015, Epilepsia.

[295]  T. Craig,et al.  HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese , 2015, Asia Pacific allergy.

[296]  J. Fagerness,et al.  Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders , 2015, Genetics research.

[297]  U. Hofmann,et al.  Heritability of metoprolol and torsemide pharmacokinetics , 2015, Clinical pharmacology and therapeutics.

[298]  Seok-joo Yoon,et al.  Differences in the Epigenetic Regulation of Cytochrome P450 Genes between Human Embryonic Stem Cell-Derived Hepatocytes and Primary Hepatocytes , 2015, PloS one.

[299]  M. Ziepert,et al.  Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. , 2015, Pharmacogenomics.

[300]  M. Hayden,et al.  Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. , 2015, Pharmacogenomics.

[301]  L. Christiansen,et al.  A twin study of the trough plasma steady-state concentration of metformin , 2015, Pharmacogenetics and genomics.

[302]  M. Debeljak,et al.  Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia , 2015, Leukemia & lymphoma.

[303]  Thachanan Kongpan,et al.  Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions , 2015, Pharmacogenetics and genomics.

[304]  J. Xavier-Neto,et al.  Signaling through retinoic acid receptors in cardiac development: Doing the right things at the right times. , 2015, Biochimica et biophysica acta.

[305]  Z. Jakab,et al.  Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity , 2015, PloS one.

[306]  K. Maggert,et al.  What Do You Mean, “Epigenetic”? , 2015, Genetics.

[307]  M. Ingelman-Sundberg,et al.  Genetic variation in the human cytochrome P450 supergene family , 2015, Pharmacogenetics and genomics.

[308]  Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes , 2015, Clinical Epigenetics.

[309]  M. Ingelman-Sundberg,et al.  Developmental Regulation and Induction of Cytochrome P450 2W1, an Enzyme Expressed in Colon Tumors , 2015, PloS one.

[310]  P. Neven,et al.  Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients , 2015, Breast Cancer Research and Treatment.

[311]  J. Lupski,et al.  Non-coding genetic variants in human disease. , 2015, Human molecular genetics.

[312]  M. Ingelman-Sundberg,et al.  Pharmacogenomic information in drug labels: European Medicines Agency perspective , 2015, The Pharmacogenomics Journal.

[313]  M. Daly,et al.  Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants , 2014, Nature.

[314]  A. Metspalu,et al.  Linking a Population Biobank with National Health Registries—The Estonian Experience , 2015, Journal of personalized medicine.

[315]  M. Pencina,et al.  Anticholinergic vs Long-Acting β-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. , 2015, JAMA.

[316]  J. Mill,et al.  Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes , 2015, Epigenetics.

[317]  O. Bernard,et al.  TET proteins and the control of cytosine demethylation in cancer , 2015, Genome Medicine.

[318]  Jie J. Zheng,et al.  Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. , 2015, JAMA.

[319]  F. Wardle,et al.  A ChIP on the shoulder? Chromatin immunoprecipitation and validation strategies for ChIP antibodies , 2015, F1000Research.

[320]  Bridget C. Ryan,et al.  ImiRP: a computational approach to microRNA target site mutation , 2016, BMC Bioinformatics.

[321]  Melissa A. Basford,et al.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.

[322]  P. Ascierto,et al.  Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. , 2016, The Lancet. Oncology.

[323]  M. Ingelman-Sundberg,et al.  Requirements for comprehensive pharmacogenetic genotyping platforms. , 2016, Pharmacogenomics.

[324]  Pao-Yang Chen,et al.  Profiling genome-wide DNA methylation , 2016, Epigenetics & Chromatin.

[325]  David R. Kelley,et al.  Basset: learning the regulatory code of the accessible genome with deep convolutional neural networks , 2015, bioRxiv.

[326]  M. Bullock,et al.  DNA Methylation Analysis: Choosing the Right Method , 2016, Biology.

[327]  J. Mill,et al.  Variation in 5-hydroxymethylcytosine across human cortex and cerebellum , 2016, Genome Biology.

[328]  K. Taylor,et al.  CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[329]  Janice M. Fullerton,et al.  Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study , 2016, The Lancet.

[330]  Lang Li,et al.  Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. , 2016, Clinical cancer research : an official journal of the American Association for Cancer Research.

[331]  Tom R. Gaunt,et al.  DNA methylation and body mass index , 2016 .

[332]  M. Ingelman-Sundberg,et al.  Precision Medicine and Rare Genetic Variants. , 2016, Trends in pharmacological sciences.

[333]  Nicholas J. Seewald,et al.  Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. , 2016, Pharmacogenomics.

[334]  A. Hofman,et al.  Blood lipids influence DNA methylation in circulating cells , 2016, Genome Biology.

[335]  M. Hayden,et al.  Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity , 2016, British journal of clinical pharmacology.

[336]  A. Sharp,et al.  Polymorphic tandem repeats within gene promoters act as modifiers of gene expression and DNA methylation in humans , 2016, Nucleic acids research.

[337]  Timothy B Sackton,et al.  Genotypic Context and Epistasis in Individuals and Populations , 2016, Cell.

[338]  C. Allis,et al.  The molecular hallmarks of epigenetic control , 2016, Nature Reviews Genetics.

[339]  M. Ingelman-Sundberg,et al.  International Journal of Molecular Sciences the Importance of Patient-specific Factors for Hepatic Drug Response and Toxicity , 2022 .

[340]  R. Fulton,et al.  PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation , 2016, Pharmacogenetics and genomics.

[341]  K. Chu,et al.  HLA‐B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine‐induced maculopapular eruption , 2016, Epilepsia.

[342]  J. Xuan,et al.  HLA-B*59:01: a marker for Stevens–Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese , 2015, The Pharmacogenomics Journal.

[343]  S. Minucci,et al.  Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia , 2016, British Journal of Cancer.

[344]  M. Schwab,et al.  DNA Methylation of ADME Genes , 2016, Clinical pharmacology and therapeutics.

[345]  S. Tiamkao,et al.  Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population , 2016, Pharmacogenetics and genomics.

[346]  Tom R. Gaunt,et al.  DNA Methylation and BMI: Investigating Identified Methylation Sites at HIF3A in a Causal Framework , 2016, Diabetes.

[347]  M. Ingelman-Sundberg,et al.  The CYP2W1 enzyme: regulation, properties and activation of prodrugs , 2016, Drug metabolism reviews.

[348]  Philip A. Ewels,et al.  Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression , 2016, Nucleic acids research.

[349]  W. Reik,et al.  Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity , 2016, Genome Biology.

[350]  P. Demoly,et al.  Genetic variants associated with drugs‐induced immediate hypersensitivity reactions: a PRISMA‐compliant systematic review , 2016, Allergy.

[351]  J. Schellens,et al.  Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[352]  U. Hofmann,et al.  Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters , 2016, Genome Medicine.

[353]  M. Nelson,et al.  HLA-DRB1*16: 01-DQB1*05 02 is a novel genetic risk factor for flupirtine-induced liver injury , 2016, Pharmacogenetics and genomics.

[354]  R. Schneider,et al.  Lateral Thinking: How Histone Modifications Regulate Gene Expression. , 2016, Trends in genetics : TIG.

[355]  M. Ingelman-Sundberg,et al.  Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics , 2017, Genetics in Medicine.

[356]  Y. Kamatani,et al.  Overview of the BioBank Japan Project: Study design and profile , 2017, Journal of epidemiology.

[357]  C. Ng,et al.  HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions , 2017, Neurology.

[358]  M. A. Moreno Hidalgo,et al.  Significant HLA class I type associations with aromatic antiepileptic drug (AED)‐induced SJS/TEN are different from those found for the same AED‐induced DRESS in the Spanish population , 2017, Pharmacological research.

[359]  P. Limprasert,et al.  HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis , 2017, Scientific Reports.

[360]  S. Subramaniam,et al.  Epigenetic Regulation: A New Frontier for Biomedical Engineers. , 2017, Annual review of biomedical engineering.

[361]  C. G. Tay,et al.  Vincristine‐induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia , 2017, Pediatric blood & cancer.

[362]  M. Ingelman-Sundberg,et al.  Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response , 2016, Genetics in Medicine.

[363]  Erica L. Kleinbrink,et al.  Association of Body Mass Index with DNA Methylation and Gene Expression in Blood Cells and Relations to Cardiometabolic Disease: A Mendelian Randomization Approach , 2017, PLoS medicine.

[364]  A. Falus,et al.  HLA-DRB1*07:01–HLA-DQA1*02:01–HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia , 2017, Haematologica.

[365]  M. Ingelman-Sundberg,et al.  Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy. , 2017, Trends in pharmacological sciences.

[366]  D. Neuberg,et al.  Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia , 2017, The Pharmacogenomics Journal.

[367]  Jie Xu,et al.  DNA methyltransferases and their roles in tumorigenesis , 2017, Biomarker Research.

[368]  L. Milani,et al.  Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments , 2017, The AAPS Journal.

[369]  J. Lieberman,et al.  Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine , 2018, The Pharmacogenomics Journal.

[370]  Tom R. Gaunt,et al.  Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity , 2016, Nature.

[371]  P. Filippakopoulos,et al.  Functions of bromodomain-containing proteins and their roles in homeostasis and cancer , 2017, Nature Reviews Molecular Cell Biology.

[372]  M. Daly,et al.  Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. , 2017, Gastroenterology.

[373]  C. Ng,et al.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population , 2016, The Pharmacogenomics Journal.

[374]  K. Chu,et al.  HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[375]  Joo-Youn Cho,et al.  Targeted Next‐Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes , 2017, Clinical pharmacology and therapeutics.

[376]  M. Carrington,et al.  Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles , 2017, Scientific Reports.

[377]  Yitian Zhou,et al.  Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects , 2017, Clinical pharmacology and therapeutics.

[378]  G. Cutting,et al.  Transformative therapies for rare CFTR missense alleles , 2017, Current opinion in pharmacology.

[379]  T. Carell,et al.  Functional impacts of 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxycytosine at a single hemi-modified CpG dinucleotide in a gene promoter , 2017, Nucleic acids research.

[380]  Q. Kan,et al.  Alterations of Histone Modifications Contribute to Pregnane X Receptor-Mediated Induction of CYP3A4 by Rifampicin , 2017, Molecular Pharmacology.

[381]  C. Sukasem,et al.  Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population , 2017, Front. Pharmacol..

[382]  M. Pirmohamed,et al.  Cost effectiveness analysis of HLA-B*58: 01 genotyping prior to initiation of allopurinol for gout , 2017, Rheumatology.

[383]  G. Koppelman,et al.  Pharmacogenetics of asthma: toward precision medicine , 2017, Current opinion in pulmonary medicine.

[384]  J. Cervera,et al.  Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia , 2017, Leukemia & lymphoma.

[385]  B. Baune,et al.  Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment , 2017, Molecular Psychiatry.

[386]  T. Kuo,et al.  Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians , 2017, Neurology.

[387]  A. Siepel,et al.  Fast, scalable prediction of deleterious noncoding variants from functional and population genomic data , 2016, Nature Genetics.

[388]  T. Park,et al.  Analysis of population-specific pharmacogenomic variants using next-generation sequencing data , 2017, Scientific Reports.

[389]  R. Fontana,et al.  Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. , 2017, Journal of hepatology.

[390]  Feng-Chi Chen,et al.  NMD Classifier: A reliable and systematic classification tool for nonsense-mediated decay events , 2017, PloS one.

[391]  C. Chu,et al.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System , 2017, International journal of molecular sciences.

[392]  Jordan M. Eizenga,et al.  Mapping DNA Methylation with High Throughput Nanopore Sequencing , 2017, Nature Methods.

[393]  P. Deloukas,et al.  Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population , 2017, The Journal of antimicrobial chemotherapy.

[394]  C. Sukasem,et al.  Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population , 2017, Pharmacogenetics and genomics.

[395]  Yi Zhang,et al.  TET-mediated active DNA demethylation: mechanism, function and beyond , 2017, Nature Reviews Genetics.

[396]  Inference about causation between body mass index and DNA methylation in blood from a twin family study , 2017, bioRxiv.

[397]  N. Krieger,et al.  Tumor Specimen Biobanks: Data Gaps for Analyzing Health Inequities—the Case of Breast Cancer , 2018, JNCI cancer spectrum.

[398]  Ming-Tsan Liu,et al.  The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. , 2018, Journal of Investigative Dermatology.

[399]  B. Gloss,et al.  Realizing the significance of noncoding functionality in clinical genomics , 2018, Experimental & Molecular Medicine.

[400]  Yitian Zhou,et al.  Comprehensive overview of the pharmacogenetic diversity in Ashkenazi Jews , 2018, Journal of Medical Genetics.

[401]  D. Reich,et al.  Multiple Sclerosis , 2018, The New England journal of medicine.

[402]  R. Mägi,et al.  Genetic variation in the Estonian population: pharmacogenomics study of adverse drug effects using electronic health records , 2018, European Journal of Human Genetics.

[403]  Fida K Dankar,et al.  The development of large-scale de-identified biomedical databases in the age of genomics—principles and challenges , 2018, Human Genomics.

[404]  G. Giles,et al.  Inference about causation between body mass index and DNA methylation in blood from a twin family study , 2017, bioRxiv.

[405]  R. Abe,et al.  An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity , 2018, Journal of immunology research.

[406]  J. Cervera,et al.  Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy , 2017, The Pharmacogenomics Journal.

[407]  M. Hadamitzky,et al.  Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy , 2018, Thrombosis and Haemostasis.

[408]  Delphine Pflieger,et al.  Proteomic Analysis of Histone Variants and Their PTMs: Strategies and Pitfalls , 2018, Proteomes.

[409]  Emily B Fabyanic,et al.  Nondestructive, base-resolution sequencing of 5-hydroxymethylcytosine using a DNA deaminase , 2018, Nature Biotechnology.

[410]  N. Hirayama,et al.  Interaction of Nevirapine with the Peptide Binding Groove of HLA-DRB1*01:01 and Its Effect on the Conformation of HLA-Peptide Complex , 2018, International journal of molecular sciences.

[411]  Yitian Zhou,et al.  Computational Methods for the Pharmacogenetic Interpretation of Next Generation Sequencing Data , 2018, Front. Pharmacol..

[412]  M. Ingelman-Sundberg,et al.  How to Consider Rare Genetic Variants in Personalized Drug Therapy , 2018, Clinical pharmacology and therapeutics.

[413]  W. Aekplakorn,et al.  Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients , 2018, Journal of immunology research.

[414]  M. Ingelman-Sundberg,et al.  Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. , 2018, The American journal of psychiatry.

[415]  R. Mägi,et al.  Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions , 2018, Genetics in Medicine.

[416]  M. Ingelman-Sundberg,et al.  Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities. , 2018, Annual review of pharmacology and toxicology.

[417]  David E. Gloriam,et al.  Pharmacogenomics of GPCR Drug Targets , 2018, Cell.

[418]  Y. Shimo,et al.  Association of HLA-A*31: 01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population , 2018, JAMA neurology.

[419]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[420]  A. Sajantila,et al.  Completed suicides of citalopram users—the role of CYP genotypes and adverse drug interactions , 2018, International Journal of Legal Medicine.

[421]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update , 2018, Clinical pharmacology and therapeutics.

[422]  M. Relling,et al.  Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group , 2018, Clinical pharmacology and therapeutics.

[423]  C. Ross,et al.  Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis , 2018, Nature Genetics.

[424]  Yitian Zhou,et al.  An optimized prediction framework to assess the functional impact of pharmacogenetic variants , 2018, The Pharmacogenomics Journal.

[425]  B. K. Park,et al.  HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. , 2018, Chemical research in toxicology.

[426]  Jingbo Wang,et al.  Architecture of polymorphisms in the human genome reveals functionally important and positively selected variants in immune response and drug transporter genes , 2018, Human Genomics.

[427]  Yitian Zhou,et al.  Integrating rare genetic variants into pharmacogenetic drug response predictions , 2018, Human Genomics.

[428]  M. Hayden,et al.  The global spectrum of protein-coding pharmacogenomic diversity , 2016, The Pharmacogenomics Journal.

[429]  A. V. van Kuilenburg,et al.  DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. , 2018, The Lancet. Oncology.

[430]  Marylyn D. Ritchie,et al.  Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects , 2018, Clinical pharmacology and therapeutics.

[431]  P. Vineis,et al.  Appraising the causal relevance of DNA methylation for risk of lung cancer , 2018, bioRxiv.

[432]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update , 2019, Clinical pharmacology and therapeutics.

[433]  A. Pavlick,et al.  Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. , 2019, Future oncology.

[434]  M. Ingelman-Sundberg,et al.  Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements , 2019, Clinical pharmacology and therapeutics.

[435]  I. Cascorbi,et al.  Implementation and obstacles of pharmacogenetics in clinical practice: An international survey , 2019, British journal of clinical pharmacology.

[436]  V. Lauschke,et al.  Genetic variability and population diversity of the human SLCO (OATP) transporter family , 2019, Pharmacological research.

[437]  Volker M. Lauschke,et al.  Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation , 2020, npj Genomic Medicine.

[438]  V. Lauschke,et al.  Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response , 2020, Journal of clinical medicine.

[439]  M. Ingelman-Sundberg,et al.  Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? , 2020, Frontiers in Psychiatry.

[440]  Xuexia Wang.  CELF 4 Variant and Anthracycline-Related Cardiomyopathy : A Children ' s Oncology Group Genome-Wide Association Study , 2022 .